**Curriculum Vitae**

**Hao Hu (胡豪)**

Institute of Chinese Medical Sciences, University of Macau

Tel: (00853)62188605; (0086)15344888605

Email: haohu@um.edu.mo

**1. Academic Background (学术背景)**

* Ph.D. in Management (2005)
  + - Sichuan University, Chengdu City, China
    - Field of studies: Medicinal administration; Healthcare innovation
* Master in Management Science and Engineering (2002)
  + - Sichuan University, Chengdu City, China
    - Field of studies: Medical management; Health technology assessment
* Bachelor in Industry Economics (1999)
  + - Harbin Engineering University, Harbin City, China
    - Field of studies: Industry organization and analysis

**2. Working Experience (工作经历)**

* Full professor (08/2020-present)
  + - Institute of Chinese Medical Sciences, University of Macau, Macao
* Associate Professor (09/2014-08/2020)
  + - Institute of Chinese Medical Sciences, University of Macau, Macao
* Assistant Professor (09/2008-08/2014)
  + - Institute of Chinese Medical Sciences, University of Macau, Macao
* Postdoctoral Research Fellow (10/2007-08/2008)
  + - Institute of Chinese Medical Sciences, University of Macau, Macao
* Postdoctoral Research Fellow (09/2006-08/2007)
  + - HEC Montréal, University of Montreal, Canada

**3. Research Focus (研究领域)**

* Biomedical data mining and computational drug repurposing & discovery
* Pharmacoepidemiology and pharmacoeconomics

**4. Research Projects(研究项目)**

1. “Study on the long-term cost-effectiveness of switching from other GLP-1 drugs to semaglutide treatment in Chinese patients with type 2 diabetes (中国2型糖尿病患者由其他GLP-1 类药物转为司美格鲁肽治疗的长期成本效果研究, CP-010-2024), Novo Nordisk (30/04/2024-30/04/2025), Principal Investigator.
2. “Research on Regulatory Framework of Using Real-world Evidence for Registration Application of Traditional Chinese Medicines Product, 真實世界證據用于中藥註冊申報的監管體系研究”, Centre for Pharmaceutical Regulatory Sciences, University of Macau (2024), Principal Investigator.
3. ”Development of mRNA vaccines for hepatocellular carcinoma therapy based on antigen binding affinity optimization and precise delivery vector design，基於抗原結合力改造與遞送載體精準設計的肝癌mRNA疫苗的研發”（0014/2023/AKP）, 2023年度澳門重點研發資助計劃(，08/06/2024-07/06/2027), team member.
4. "Research on the Development of Licensed Pharmacist (執業藥師發展研究)“, China Pharmaceutical University (01/10/2023-31/12/2024), Principal Investigator.
5. “Pharmacoepidemiological and Pharmacoeconomic Evaluation of Targeted Therapies and Immune Therapies for Hepatocellular Carcinoma Based on Electronic Health Records Databases (基於電子健康檔案數據庫的肝細胞癌靶向治療和免疫治療的藥物流行病學和藥物經濟學評價) MYRG-GRG2023-00059-ICMS”, University of Macau (01/01/2024-31/12/2025), Principal Investigator.
6. “Optimizing therapeutic strategy of immune checkpoint inhibitors for advanced hepatocellular carcinoma through integrative investigation of pharmacometrics, epidemiology, and pharmacoeconomics (通過定量藥理學、流行病學和藥物經濟學的整合分析以優化免疫檢查點抑制劑治療晚期肝細胞癌的策略MYRG2022-00113-ICMS)”, University of Macau (01/01/2023-31/12/2024), Principal Investigator.
7. “Development and verification of clinical trial guideline for traditional Chinese medicines for nonalcoholic steatohepatitis for regulatory review (用於監管審評的中藥治療非酒精性脂肪肝肝炎的臨床實驗指導原則的開發與驗證, SKL-QRCM-IRG2023-031). State Key Laboratory of Quality Research in Chinese Medicine (UM) Internal Research Grant (IRG) 2023.
8. “Exploratory development of Chinese medicine products for non-alcoholic steatohepatitis (NASH) through model-based clinical trial simulation (QRCM-IRG2022-009). State Key Laboratory of Quality Research in Chinese Medicine (UM) Internal Research Grant (IRG) 2022.
9. “Real-World Big Data Study on Key Maternal and Child-Specific Diseases (CP-013-2020)”, Foshan Women and Children Hospital (2021-2022), Principal Investigator.
10. “Climate Medicine Industry Research”, Beijing Health Promotion Association (2020), Principal Investigator.
11. “Evaluation and Innovation of Market Access Policy for Chinese Herbal Medicine Products (中草藥產品市場准入政策的評估與創新)”, University of Macau (01/01/2021-31/12/2022), Principal Investigator.
12. “Pharmacoepidemiology Study of Chinese Herbal Medicine and Conventional Medicine for Asthma: Implications for Drug Therapy and Drug Development (草藥與常規藥物治療哮喘的藥物流行病學研究：對藥物治療與藥物開發的啟示MYRG2019-00025-ICMS”, University of Macau (01/01/2020-31/21/2021), Principal Investigator.
13. “Research on Classification Management Policy of Community Pharmacy (零售藥店分類分級管理制度相關政策研究”, Beijing Health Promotion Association (2019), Principal Investigator.
14. “Research on Pharmaceutical Care Guideline for Chronic Obstructive Pulmonary Disease (COPD) at Community Pharmacy (社会药房慢性阻塞性肺疾病（COPD）药学服务指导规范研究)”, National Center for Licensed Pharmacist Development (07/2019-12/2020), Principal Investigator.
15. “Evidence-based Development and Test of Integrative Pharmaceutical Care Standard of Chinese Medicine and Western Medicine by Licensed Pharmacist执业药师提供中西药并用药学服务标准的循证构建与验证研究(ndrplc201904)”, National Center for Licensed Pharmacist Development (07/2019-12/2020), Principal Investigator.
16. “International Comparative Study on Development Trends and Policy Application of Real-World Evidence (RWE) 真实世界证据开发趋势和政策应用的国际比较研究”, National Medical Products Administration of China (2019), Principal Investigator.
17. “Research on Development Trend and Policy Dynamics of Smart Hospital智慧医院的发展趋势和政策动态研究”, Beijing Health Promotion Association (2019), Principal Investigator.
18. “Comprehensive Evaluation of Clinical Rational Application of Perioperative Analgesic Drugs围手术期镇痛药物临床合理应用综合评价”, International Research Center of Medicinal Administration at Peking University (2019), Co-Principal Investigator.
19. “Comprehensive Evaluation of Rational Use of Gastrodin Injection天麻素注射液合理用药综合评价”, International Research Center of Medicinal Administration at Peking University (2019), Co-Principal Investigator.
20. “Pharmaceutical Care of Licensed Pharmacists for Respiratory Disease at Community Pharmacies in China”, Beijing Health Promotion Association (08/2018-03/2019), Principal Investigator.
21. “Research on Community Pharmacist’s Responsibility on Pharmaceutical Care towards Traditional Medicine/Complementary Medicine Products: Survey in China and Australia (MYRG2018-00012-ICMS)”, University of Macau (2018-2019), Principal Investigator.
22. “Study on Biosynthesis Pathway of Icariin and Its Reconstruction and Optimization in Budding Yeast天然活性產物淫羊藿苷的生物合成通路研究及其在釀酒酵母中的重建和優化 (031/2017/A1)”, FDCT (2018-2020), Principal Investigator.
23. “Development and Application of Integrative Pharmaceutical care of Traditional Chinese Medicine and Western Medicine for Licensed Pharmacists (执业药师中西药结合药学服务标准的制订与应用研究)”, National Center for Licensed Pharmacist Development (2018), Principal Investigator.
24. “Evidence-based Medicine and Big Data Analysis of Medical Insurance for the Treatment of Chronic Respiratory Diseases in China中国慢性呼吸疾病规范治疗循证医学及医保大数据分析”, International Research Center of Medicinal Administration at Peking University (2018), Co-Principal Investigator.
25. “Hydropower resource development and protection and propagation of rare plant species population”, State Key Laboratory of Hydraulics and Mountain River Engineering Sichuan University (2017-2018), Principal Investigator.
26. “Providing Integrative Pharmaceutical Care of Traditional Chinese Medicine and Western Medicine by Community Pharmacists at Community Pharmacies (社会药房执业药师提供中西药结合的药学服务研究)”, National Center for Licensed Pharmacist Development (2017), Principal Investigator.
27. “Economic Evaluation of Quality Control Interventions on COPD”, Project Hope (2017-2019), Principal Investigator.
28. “Development of Commercial Health Insurance and Pharma Strategies in China: Opportunities, Challenges and Strategic suggestions”, International Research Center of Medicinal Administration at Peking University (2017), Principal Investigator.
29. “Technology Innovation and Commercialization of Gene Therapy: A Sustainable Innovation System Perspective”, University of Macau (2016-2018), Principal Investigator.
30. “Development of water resource and sustainable utlization of rare medicinal plants”, State Key Laboratory of Hydraulics and Mountain River Engineering Sichuan University (01/04/2015-31/05/2017), Principal Investigator.
31. “Attitudes, knowledge, pharmacy practice and barriers of community pharmacists towards Traditional Medicine products in China” MYRG2015-00072-ICMS-QRCM”, University of Macau, Principal Investigator.
32. “Research on Strategic Choice of Corporate Branding under Competing Institutional Logics”, China NSFC (2013-2014), Project Collaborator.
33. “Universities and Contract Research Organizations as Actors of Regional, Sectoral Innovation System in Emerging Bioscience Clusters and TCM Science Park: Driver, Configuration, & Innovation”, University of Macau (2012-2014), Principal Investigator.
34. “Drug Security and Pharmaceutical Care Service of Macau Community Pharmacies: Examining a Bilateral Perspective”, University of Macau (2012-2013), Principal Investigator.
35. “Sectoral System of Innovation of Traditional Chinese Medicine under the Transition of Global Pharmaceutical Industry”, University of Macau (2010-2011), Principal Investigator.
36. “Innovative Capabilities in the Aerospace Industry”, Canada SSHRC (2009-2012), Project Collaborator
37. “Technology Transfer and Industrialization Evaluation of TCM R&D”, University of Macau (2009-2010), Principal Investigator.
38. “Sci-Tech Innovation and Intellectual Property Valuation of Chinese Medicine”, University of Macau (2008-2009), Principal Investigator.

**5. Journal articles in English (英文期刊发表)**

1. Deng N#, Yan Z#, Wang S, Song M\*, **Hu H\***. Utilization of immune checkpoint inhibitors in HER2-negative, advanced metastatic or unresectable gastric cancer under all CPS grading: evaluation of efficacy based on individual patient data reconstruction and secondary analyses. *Clinical Therapeutics，*.
2. Ruan Z#, Chen X#, Song M, Jia R, Luo H, Ung COL, **Hu H\***. Real-world utilization and effectiveness of glucagon-like peptide-1 receptor agonists dosed weekly and daily in patients with type 2 diabetes mellitus: results from retrospective electronic medical records in China. *Diabetes, Metabolic Syndrome and Obesity*, 2024;17: 3657–3666.
3. Lei PK#, Liu Z#, Ung CO, **Hu H\***. Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis. *BMC Gastroenterology*. 2024; 24: 331.
4. Zhou H, Li Y, Yang J, Li Y, Ung CO, **Hu H**, Song M\*. Common scenarios of off-label psychotropic medication use in adolescents with depression in China: the extent of evidence. *Asian Journal of Psychiatry*. 2024;98:104123.
5. Zou H, Ge Y, Chen W, Yao D, Ung CO, Lai Y\*, **Hu H\***. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors. *International Immunopharmacology*. 2024;132:111947.
6. Ge Y, Yao D, Ung CO, Xue Y, Li M, Lin J, **Hu H\***, Lai Y\*. Digital medical information services delivered by pharmaceutical companies via WeChat: qualitative analytical study. *Journal of Medical Internet Research*. 2023;25:e43812.
7. Zou H, Xue Y, Chen X, Lai Y, Yao D, Ung COL, **Hu H\***. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma. *PLOS ONE*. 2023; 18(10): e0292239.
8. Xue Y, Zou H, Ruan Z, Chen X, Lai Y, Yao D, Ung COL\*, **Hu H\***. Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature. *Frontiers in Endocrinology*. 2023;14:1254398.
9. Chen X, Shi J, Lai Y, Xue Y, Ung COL\*, Hu H\*. Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design. *Chinese Medicine*. 2023;18:58.
10. Lei KC, Loi CI, Cen Z, Li J, Liang Z, Hu H, Chan TF, Ung COL\*. Adopting an electronic medication administration system in long-term care facilities: a key stakeholder interview study in Macao. *Informatics for Health and Social Care*. 2023; 19:1-5.
11. Ruan Z, Jiang Y, Shi H, Jia R, Ung CO, Hu H\*. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. *Expert Review of Clinical Pharmacology*. 2023; 16(2): 161-176.
12. Xue Y, Ruan Z, Ung, COL, Lai Y, & Hu H\*. Policy analysis of system responses to addressing and reversing the obesity trend in China: a documentary research. *BMC Public Health*. 2023; 23(1): 1198.
13. Yan X, Zou H, Lai Y, Ung CO, Hu H\*. Efficacy and safety of first-line targeted treatment and immunotherapy for patients with biliary tract cancer: a systematic review and meta-analysis. *Cancers*. 2023;15(1):39.
14. Zou H, Lei Q, Yan X, Lai Y, Ung CO, Hu H\*. Clinical outcomes associated with monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for advanced hepatocellular carcinoma in real-world practice: a systematic literature review and meta-analysis. *Cancers*. 2023;15(1):260.
15. Lei Q, Yan X, Zou H, Jiang Y, Lai Y, Ung CO, Hu H\*. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. *Discover Oncology*. 2022;13(1):95.
16. Hu H\*, Su J, Ma J. Smart hospital innovation: technology, service, and policy. *Frontiers in Public Health*. 2022;10:845577.
17. Lai Y, Wang R, Li W, Zhu H, Fei S, Shi H, Lu N, Ung COL, Hu H\*, Han S\*. Clinical and economic analysis of Gastrodin injection for dizziness or vertigo: a retrospective cohort study based on electronic health records in China. *Chinese Medicine*. 2022;17: 6.
18. Lin Q, Xue Y, Zou H, Ruan Z, Ung CO, Hu H\*. Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials. *Expert Review of Clinical Pharmacology*. 2022;15(12):1461-9.
19. Liu L, Ruan Z, Ung CO, Zhang Y, Shen Y, Han S, Jia R, Qiao J, Hu H\*, Guo L\*. Long-term cost-effectiveness of subcutaneous once-weekly semaglutide versus polyethylene glycol loxenatide for treatment of type 2 diabetes mellitus in China. *Diabetes Therapy*. 2022; 14(1):93-107.
20. Perugini M, Johnson TJ, Beume TM, Dong OM, Guerino J, Hu H, Kerr K, Kindilien S, Nuijten M, Ofili TU, Taylor M. Are we ready for a new approach to comparing coverage and reimbursement policies for medical nutrition in key markets: an ISPOR Special Interest Group report. *Value in Health*. 2022;25(5):677-84.
21. Ruan Z, Zou H, Lei Q, Ung COL, Shi H, Hu H\*. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2022; 22(4): 555-574.
22. Ruan Z, Ung CO, Shen Y, Zhang Y, Wang W, Luo J, Zou H, Xue Y, Wang Y, Hu H\*, Guo L\*. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China. *Diabetes Therapy*. 2022; 13:1737-1753.
23. Ung COL, Hu Y, Hu H, Bian Y. Investigating the intention to receive the COVID-19 vaccination in Macao: implications for vaccination strategies. *BMC Infectious Diseases*. 2022; 22: 218.
24. Xia C, Yao D, Lai Y, Xue Y, Hu H\*. Market access of Chinese patent medicine products to healthcare security system in China: implications for international integration of traditional medicine into health systems. *Chinese Medicine*. 2022;17:5.
25. Zeng P, Tian Z, Han Y, Zhang W, Zhou T, Peng Y, Hu H, Cai J. Comparison of ONT and CCS sequencing technologies on the polyploid genome of a medicinal plant showed that high error rate of ONT reads are not suitable for self-correction. *Chinese Medicine*. 2022;17:94.
26. Zou H, Ge Y, Lei Q, Ung CO, Ruan Z, Lai Y, Yao D, Hu H\*. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: A systematic review. *Hepatology International*. 2022; 16:27–37.
27. Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, Lai Y, Ung COL\*, Hu H\*. Economic burden and quality of life of hepatocellular carcinoma in greater China: a systematic review. *Frontiers in Public Health*. 2022;21:767.
28. Chen X, Yang L, Liu X, Zhu H, Yu F, Ung CO, Hu H, Chan W, Shi H\*, Han S\*. Drug utilization for pain management during perioperative period of total knee arthroplasty in China: a retrospective research using real-world data. *Medicina*. 2021;57(5):451.
29. Lai Y, Chen S, Li M, Ung CO, Hu H\*. Policy interventions, development trends, and service innovations of internet hospitals in China: documentary analysis and qualitative interview study. *Journal of Medical Internet Research*. 2021;23(7): e22330.
30. Jiang Y, Hu H, Leung SW\*. Comparative efficacy of single-inhaler triple therapies for COPD: a protocol for systematic review and network meta-analysis. *PloS one*. 2021; 16(8): e0255545.
31. Lei C, Yang L, Lou CT, Yang F, SiTou KI, Hu H, Io K, Cheok KT, Pan B, Ung CO\*. Viral etiology and epidemiology of pediatric patients hospitalized for acute respiratory tract infections in Macao: a retrospective study from 2014 to 2017. *BMC Infectious Diseases*. 2021;21: 306.
32. Li J, Hu H, Liu W, Lei CI, Ung COL\*. Predicting pharmacist intention to contribute to COVID-19 management at the community level: a cross-sectional survey study. *Frontiers in Public Health*. 2021; 9: 653335.
33. Li M, Cheng K, Ku K, Li J, Hu H\*, Ung CO\*. Factors influencing the length of hospital stay among patients with chronic obstructive pulmonary disease (COPD) in macao population: a retrospective study of inpatient health record. *International Journal of Chronic Obstructive Pulmonary Disease*. 2021;16:1677.
34. Li M, Chen S, Lai Y, Liang Z, Wang J, Shi J, Lin H, Yao D, Hu H\*, Ung CO\*. Integrating real-world evidence in the regulatory decision-making process: a systematic analysis of experiences in the US, EU, and China using a logic model. *Frontiers in Medicine*. 2021; 8:778.
35. Li M, Chen S, Zhao H, Tang C, Lai Y, Ung CO, Su J\*, Hu H\*. The short-term associations of chronic obstructive pulmonary disease hospitalizations with meteorological factors and air pollutants in Southwest China: a time-series study. *Scientific Reports*. 2021;11:12914.
36. Li X, Chen W, Simal-Gandara J, Georgiev MI, Li H, Hu H, Wu X, Efferth T, Wang S. West meets east: open up a dialogue on phytomedicine. *Chinese Medicine*. 2021;16: 57.
37. Li X, Chen W, Xu Y, Liang Z, Hu H, Wang S, Wang Y. Quality evaluation of randomized controlled trials of rhodiola species: a systematic review. *Evidence-Based Complementary and Alternative Medicine*. 2021;2021: 9989546.
38. Liang Z, Chen X, Shi J, Hu H, Xue Y, Ung CO. Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials. *Chinese Medicine*. 2021 Dec;16: 9.
39. Liang Z, Lai Y, Li M, Shi J, Lei CI, Hu H, Ung CO\*. Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications. *Chinese Medicine*. 2021;16: 23.
40. Ruan Z, Yang L, Shi H, Yue X, Wang Y, Liang M, Hu H\*. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 diabetes: a systematic literature review. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2021, 21(2):221-233.
41. Salem A, Zhong H, Ramos M, Lamotte M, Hu H\*. Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China. *BMJ open*. 2021;11(4):e043664.
42. Shi H, Chen X, Liu X, Zhu H, Yu F, Ung CO, Chan WS, Hu H\*, Han S\*. National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018. *Journal of Pharmaceutical Policy and Practice*. 2021; 14:45.
43. Xue Y, Peng Y, Geng Z, Wang Y, Ung COL, Hu H\*. Metal–organic frameworks (MOFs) based analytical techniques for food safety evaluation. *eFood*. 2021; 2(1):1-12.
44. Yao PF, Gao Y, Simal-Gandara J, Farag MA, Chen W, Yao D, Delmas D, Chen Z, Liu K, Hu H, Xiao J. Litchi (Litchi chinensis Sonn.): a comprehensive review of phytochemstry, medicinal properties, and product development. *Food & Function*. 2021; 12(20): 9527-9548.
45. Zhang W, Zhang G, Zeng P, Zhang Y, Hu H, Liu Z, Cai J\*. Genome sequence of Apostasia ramifera provides insights into the adaptive evolution in orchids. *BMC Genomics*. 2021; 22: 536.
46. Chen LX, Lai YF, Zhang WX, Cai J, Hu H\*, Wang Y, Zhao J\*, Li SP\*. Comparison of volatile compounds in different parts of fresh Amomum villosum Lour. from different geographical areas using cryogenic grinding combined HS–SPME–GC–MS. *Chinese Medicine*. 2020; 15: 97.
47. Cheong ST, Li J, Ung CO, Tang D, Hu H\*. Building an innovation system of medical devices in China: Drivers, barriers, and strategies for sustainability. *SAGE open medicine*. 2020; 8: 1-14.
48. Harnett JE, Desselle SP, Hu H, Ung CO. Involving systems thinking and implementation science in pharmacists’ emerging role to facilitate the safe and appropriate use of traditional and complementary medicines. *Human Resources for Health*. 2020; 18: 55.
49. Hu Y, Yao D, Ung CO, Hu H\*. Promoting community pharmacy practice for chronic obstructive pulmonary disease (COPD) management: a systematic review and logic model. *International Journal of Chronic Obstructive Pulmonary Disease*. 2020;15:1863.
50. Pang NI, Bie R, Ung CO, Hu H\*. Development and validation of a logic model for utilization of nutrition support among patients with cancer. BioMed Research International. 2020; 2020: 4513719.
51. Shi L, Chang J, Liu X, Zhai P, Hu S, Li P, Hayat K, Kabba JA, Feng Z, Yang C, Jiang M. Dispensing antibiotics without a prescription for acute cough associated with common cold at community pharmacies in shenyang, northeastern china: A cross-sectional study. Antibiotics. 2020; 9(4): 163.
52. Wei J, Xue Y, Dong J, Wang S, Hu H, Gao H, Li P, Wang Y. A new fluorescent technique for pesticide detection by using metal coordination polymer and nanozyme. Chinese Medicine. 2020; 15: 22.
53. Yang L, Chen X, Oi Lam Ung C, Zhu H, Hu H**\***, Han S\*. Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China. Front. Pharmacol. 2020; 11: 887.
54. Yao D, **Hu H**, Harnett JE, Ung COL. Integrating traditional Chinese medicines into professional community pharmacy practice in China-Key stakeholder perspectives. *European Journal of Integrative Medicine*. 2020, 101063.
55. Yao D, Hu Y, Harnett JE, Hu H\*, Ung COL\*. Community pharmacist's perceptions and practice behaviors related to traditional and complementary medicines in China: a cross-sectional study. *European Journal of Integrative Medicine*. 2020; 40: 101225.
56. Zhang W, Ung COL, Lin G, Liu J, Li W, Hu H\*, Xi X\*. Factors contributing to patients’ preferences for primary health care institutions in China: a qualitative study. Front. Public Health 2020, 8:414
57. Zheng T, Chen W, Hu H, Wang Y, Harnett JE, Ung CO. The prevalence, perceptions and behaviors associated with traditional/complementary medicine use by breastfeeding women living in Macau: a cross-sectional survey study. BMC Complementary Medicine and Therapies. 2020; 20: 122.
58. Chen S, Bie R, Lai Y, Shi H, Ung COL, **Hu H**\*. Trends and development in enteral nutrition application for ventilator associated pneumonia: a scientometric research (1996-2018). *Frontiers in Pharmacology*. 2019; 10: 246. (SCI)
59. Han Y, Zhang W, Zeng P, **Hu H**, Wang Y, Cai J. The complete chloroplast genome of the essential medicinal herb, *Amomum Villosum* (Zingiberaceae). *Mitochondrial DNA Part B*. 2019; *4*(1): 1798-1799. (SCI)
60. Guo P, Yang W, **Hu H**, Wang Y, Li P. Rapid detection of aflatoxin B 1 by dummy template molecularly imprinted polymer capped CdTe quantum dots. *Analytical and Bioanalytical Chemistry*. 2019; 411(12): 2607-2617. (SCI)
61. Harnett JE, Ung COL, **Hu H**, Sultani M, Desselle SP. Advancing the pharmacist’s role in promoting the appropriate and safe use of dietary supplements. *Complementary Therapies in Medicine*. 2019; 44: 174-181. (SCI)
62. Hayat K, Rosenthal M, Gillani AH, Zhai P, Aziz MM, Ji W, Chang J, **Hu H**, Fang Y. Perspective of Pakistani physicians towards hospital antimicrobial stewardship programs: a multisite exploratory qualitative study. *International Journal of Environmental Research and Public Health*. 2019; *16*(9): 1565. (SCI)
63. Shi H, Guo W, Zhu H, Li M, Ung COL, **Hu H\***, Han S. Cost-effectiveness analysis of Xiyanping Injection (Andrographolide Sulfonate) for treatment of adult community acquired pneumonia: a retrospective, propensity score-matched cohort study. *Evidence-Based Complementary and Alternative Medicine*. 2019; 2019: 4510591. (SCI)
64. Shi J, **Hu H**, Harnett J, Zheng X, Liang Z, Wang YT, Ung COL. An evaluation of randomized controlled trials on nutraceuticals containing traditional Chinese medicines for diabetes management: a systematic review. *Chinese Medicine*. 2019, 14(1): 54.
65. Song Q, Ung COL, Tang D, **Hu H\***. The use of microblog “Weibo” by Chinese Patent Medicine companies in China. *Therapeutic Innovation & Regulatory Science*, 2019; 53(4): 460-469. (SCI)
66. Tang D, Choi WI, Deng L, Bian Y, **Hu H\***. Health status of children left behind in rural areas of Sichuan Province of China: a cross-sectional study. *BMC International Health and Human Rights*. 2019; 19: 4. (SSCI)
67. Tang D, Li M, Ung COL, Tang C, **Hu H\***. Exploratory study on development challenges of maternal and child healthcare institutions in China: a qualitative study combining interviews and focus groups. *BMJ Open*. 2019; 9(6): e028789. (SCI)
68. Ung COL, Harnett JE, **Hu H**, Desselle SP. Barriers to pharmacists adopting professional responsibilities that support the appropriate and safe use of dietary supplements in the United States: Perspectives of key stakeholders. *American Journal of Health-System Pharmacy*. 2019; *76*(13): 980-990. (SCI)
69. Xi X, Huang Y, Lu Q, Ung COL, **Hu H**\*. Community pharmacists’ opinions and practice of pharmaceutical care at chain pharmacy and independent pharmacy in China. *International Journal of Clinical Pharmacy*. 2019; 41: 478-487. (SCI)
70. Xi X, Lu Q, Wo T, Pei P, Lin G, **Hu H**, Ung COL. Doctor’s presenteeism and its relationship with anxiety and depression: a cross-sectional survey study in China. *BMJ Open*. 2019; 9: e028844. (SCI)
71. Yang L, Li L, **Hu H**, Wan J, Li P. Natural deep eutectic solvents for simultaneous extraction of multi-bioactive components from *Jinqi Jiangtang* Preparations. *Pharmaceutics*. 2019;11(1):18. (SCI)
72. Zheng T, Yao D, Chen W, **Hu H**, Ung COL, Harnett JE. Healthcare providers' role regarding the safe and appropriate use of herbal products by breastfeeding mothers: a systematic literature review. *Complementary Therapies in Clinical Practice*. 2019; *35:* 131-147. (SCI)
73. Cao JL, Wang SS, **Hu H**, He CW, Wan JB, Su HX, Wang YT, Li P. Online comprehensive two-dimensional hydrophilic interaction chromatography× reversed-phase liquid chromatography coupled with hybrid linear ion trap Orbitrap mass spectrometry for the analysis of phenolic acids in Salvia miltiorrhiza. *Journal of Chromatography A.* 2018; 1536: 216-227. (SCI)
74. Chen H, Ung CO, Chi P, Wu J, Tang D, **Hu H**\*. Consumers’ perceptions about pharmaceutical care provided by community pharmacists in China in relation to over-the-counter drugs: a qualitative study. *Inquiry*. 2018; 55: 0046958018793292. (SSCI)
75. Choi WI, Shi H, Bian Y, **Hu H\***. Development of commercial health insurance in China: a systematic literature review. *BioMed Research International*. 2018; 2018: 3163746. (SCI)
76. Chung CC, **Hu H\***. Divergent trajectories of sectoral evolution: the case of Traditional Chinese Medicine in China (1949–2015). *Technological Forecasting and Social Change*. 2018; 128: 252-261. (SSCI)
77. Dong P†, **Hu H**†, Guan X, Ung CO, Shi L, Han S, Yu S. Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease. *Chinese Medicine*. 2018; 13(1): 28. (SCI)
78. Kong X, Zhang Q, Lai Y, **Hu H**, Chen X, Hu Y. Global patent landscape of programmed cell death 1: implications of the rapid expansion. *Expert Opinion on Therapeutic Patents*. 2018; 28(1): 69-80. (SCI)
79. Lai Y, Suo S, Wang R, Kong X, Hu Y, Tang D, Shi H, Chen S, **Hu H**\*. Trends involving monoclonal antibody (mAb) research and commercialization: a scientometric analysis of IMS Lifecycle R&D Focus Database (1980–2016). *Human Vaccines & Immunotherapeutics*. 2018; 14(4): 847-855. (SCI)
80. Li J, Zhu J, **Hu H**, Harnett JE, Lei CI, Chau KY, Chan G, Ung COL. Internationalization of Traditional/Complementary Medicine products: market entry as medicine. *Chinese Medicine*. 2018; 13(1): 50. (SCI)
81. Li M, Wang F, Chen R, Liang Z, Zhou Y, Yang Y, Chen S, Ung COL\*, **Hu H\***. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. *International Journal of Chronic Obstructive Pulmonary Disease*. 2018; 13: 3349-3357. (SCI)
82. Lin AX, Chan G, Hu Y, Ouyang D, Ung COL, Shi L, **Hu H**\*. Internationalization of traditional Chinese medicine: current international market, internalization challenges and prospective suggestions. *Chinese Medicine*. 2018; 13(1): 9. (SCI)
83. Lin X, Hu H, Liu Y, Guan X, Song J, Shi L. The comprehensive influence of firm-level factors on drug product internationalization of Chinese pharmaceutical firms. *Journal of Chinese Pharmaceutical Sciences*. 2018; 27(3): 209-214.
84. Suo S, Lai Y, Li M, Song Q, Cai J, Zhao J, Yang Q, Ung CO, **Hu H\***. Phytochemicals, pharmacology, clinical application, patents, and products of Amomi fructus. *Food and Chemical Toxicology*. 2018; 119: 31-36. (SCI)
85. Ung COL, Harnett J, **Hu H\***. Development of a strategic model for integrating complementary medicines into professional pharmacy practice. *Research in Social and Administrative Pharmacy*. 2018; 14(7): 663-672. (SCI)
86. Zhang W, Zhong H, Wang Y, Chan G, Hu Y, **Hu H**, Ouyang D. Academic career progression of Chinese-origin pharmacy faculty members in Western countries. *Pharmacy*. 2018; 6: 104.
87. Zhong H, Chan G, Hu Y, **Hu H**, Ouyang D. A comprehensive map of FDA-approved pharmaceutical products. *Pharmaceutics*. 2018; 10(4): 263. (SCI)
88. Zou H, Li R, **Hu H**, Hu Y, Chen X. Modulation of regulatory T cell activity by TNF receptor type II-targeting pharmacological agents. *Frontiers in Immunology.* 2018; 9: 594. (SCI)
89. Cai Y, Li P, Li XW, Zhao J, Chen H, Yang Q, **Hu H**\*. Converting Panax ginseng DNA and chemical fingerprints into two-dimensional barcode. *Journal of Ginseng Resesarch.* 2017; 41(3): 339-346. (SCI)
90. Kong X, Wan JB, **Hu H**, Su S, Hu Y. Evolving patterns in a collaboration network of global R&D on monoclonal antibodies. *mAbs.* 2017; 9(7): 1041-1051. (SCI)
91. Lai Y, Wang R, Chen X, Tang D, Hu Y, Cai J, Zhang Q, **Hu H**\*. Emerging trends and new developments in monoclonal antibodies: a scientometric analysis (1980–2016). *Human Vaccines & Immunotherapeutics*. 2017; 13(6): 1388-1397. (SCI)
92. Ni J, Zhao J, Ung COL, Hu Y, **Hu H**, Wang Y. Obstacles and opportunities in Chinese pharmaceutical innovation. *Globalization and Health.* 2017; 13(1): 21. (SSCI)
93. Song M, Ung COL, Lee VWY, Hu Y, Zhao J, Li P, **Hu H**\*. Community pharmacists’ perceptions about pharmaceutical service of over-the-counter traditional Chinese medicine: a survey study in Harbin SCI of China. *BMC Complementary and Alternative Medicine*. 2017; 17(1): 9. (SCI)
94. Ung COL, Harnett J, **Hu H**\*. Community pharmacist's responsibilities with regards to Traditional Medicine/Complementary Medicine products: a systematic literature review. *Research in Social and Administrative Pharmacy*, 2017; 13(4): 686-716. (SSCI)
95. Ung COL, Harnett J, **Hu H\***. Key stakeholder perspectives on the barriers and solutions to pharmacy practice towards complementary medicines: an Australian experience. *BMC Complementary and Alternative Medicine*. 2017; 17(1): 394. (SCI)
96. Wang, L., Suo, S., Li, J., Hu, Y., Li, P., Wang, Y., & **Hu, H\***. An investigation into traditional Chinese medicine hospitals in China: development trend and medical service innovation. *International Journal of Health Policy and Management*, (2017). *6*(1), 19. (SSCI)
97. Wei J, Cao J, **Hu H**, Yang Q, Yang F, Wan J, Su H, He C, Peng Li, Wang Y. Sensitive and selective detection of oxo-form organophosphorus pesticides based on CdSe/ZnS quantum dots. *Molecules*. 2017; *22*(9): 1421. (SCI)
98. Wu X, Gao H, Sun W, Yu J, **Hu H**, Xu Q, Chen X. Nepetoidin B, a natural product, inhibits LPS‐stimulated nitric oxide production via modulation of iNOS mediated by NF‐κB/MKP‐5 pathways. *Phytotherapy Research*. 2017; 31: 1072-1077. (SCI)
99. Yao D, Xi X, Huang Y, **Hu H**, Hu Y, Wang Y, Yao W. A national survey of clinical pharmacy services in county hospitals in China. *PloS one*. 2017; 12(11): e0188354. (SCI)
100. Zhang Q, Yu H, Qi J, Tang D, Chen X, Wan JB, Li P, **Hu H**, Wang YT, Hu Y. Natural formulas and the nature of formulas: exploring potential therapeutic targets based on traditional Chinese herbal formulas. *PloS one*. 2017; *12*(2): e0171628. (SCI)
101. Zhou Y, Wang C, Wang R, Lin L, Yin Z, **Hu H**, Yang Q, Zhang Q. Preparative separation of four sesquiterpenoids from Curcuma longa by high-speed counter-current chromatography. *Separation Science and Technology*. 2017; 52(3): 497-503. (SCI)
102. Cai Y, Li X, Wang R, Yang Q, Li P, **Hu H**\*. Quality traceability system of traditional Chinese medicine based on two dimensional barcode using mobile intelligent technology. *PloS one.* 2016; *11*(10): e0165263. (SCI)
103. Chao CK, **Hu H\***, Zhang L, Wu J. Managing the challenges of pharmaceutical patent expiry: a case study of Lipitor. *Journal of Science and Technology Policy Management*. 2016; *7*(3): 258-272.
104. Chen X, Ung COL, **Hu H**\*, Liu X, Zhao J, Hu Y, Li P, Yang Q. Community pharmacists’ perceptions about pharmaceutical care of traditional medicine products: a questionnaire-based cross-sectional study in Guangzhou, China. *Evidence-Based Complementary and Alternative Medicine:* 2016; 2016: 7801637. (SCI)
105. Hafsi T, **Hu H**\*. Sectoral innovation through competing logics: the case of antidepressants in traditional Chinese medicine. *Technological Forecasting and Social Change*. 2016; 107:80-89. (SSCI)
106. **Hu H**, Wu J, Shi J. Strategic HRM and organisational learning in the Chinese private sector during second-pioneering. *International Journal of Human Resource Management*. 2016; 27(16): 1813-1832. (SSCI)
107. Lai YF, Chen LX, Chen YN, Zhao J, Leong F, Li XW, Yang Q, Li P, **Hu H**\*. Sustainable development of *Amomum Villosum*: A systematic investigation on three production modes. *African Journal of Traditional, Complementary & Alternative Medicines*, 2016; 13(4): 97-104. (SCI)
108. Lin LG, Ung CO, Feng ZL, Huang L, **Hu H**. Naturally occurring diterpenoid dimers: source, biosynthesis, chemistry and bioactivities. *Planta Medica.* 2016; 82(15): 1309-1328. (SCI)
109. Ren W, Zuo R, Wang YN, Wang HJ, Yang J, Xin SK, Han LY, Zhao HY, Han SY, Gao B, **Hu H**. Pharmacokinetic-pharmacodynamic analysis on inflammation rat model after oral administration of Huang Lian Jie Du decoction. *PloS one*. 2016; 11(6): e0156256. (SCI)
110. Song M, Guo H, Chen H, **Hu H**\*. Characteristics of anti-cancer drug studies registered on the Chinese Clinical Trial Registry (ChiCTR) from 2007 to 2015. *Journal of Evidence-Based Medicine*. 2016; 9(2): 59-68.
111. Ung COL, Chao CK, Hu Y, Zhao J, Li P, Wang Y, **Hu H**\*. Community pharmacists’ understanding, attitudes, practice and perceived barriers related to providing pharmaceutical care: a questionnaire survey in Macao. *Tropical Journal of Pharmaceutical Research. 2016;* 15(4): 847-854. (SCI)
112. Wei JC, Hu J, Cao JL, Wan JB, He CW, Hu YJ, **Hu H**, Li P. Sensitive detection of organophosphorus pesticides in medicinal plants using ultrasound-assisted dispersive liquid–liquid microextraction combined with sweeping micellar electrokinetic chromatography. *Journal of Agricultural and Food Chemistry*. 2016; 64(4): 932-940. (SCI)
113. Zuo R, Ren W, Bian BL, Wang HJ, Wang YN, **Hu H**, Zhao HY, Si N. Metabolic fate analysis of Huang–Lian–Jie–Du Decoction in rat urine and feces by LC–IT-MS combining with LC–FT-ICR-MS: a feasible strategy for the metabolism study of Chinese medical formula. *Xenobiotica*. 2016; 46(1): 65-81. (SCI)
114. Cai Y, Li X, Li M, Chen X, **Hu H\*,** Ni J, Wang Y. Traceability and quality control in traditional Chinese medicine: from chemical fingerprint to two-dimensional barcode. *Evidence-Based Complementary and Alternative Medicine.* 2015; 2015: 251304. (SCI)
115. Geng X, Kong X, **Hu H**, Chen J, Yang F, Liang H, Chen X, Hu Y. Research and development of therapeutic mAbs: An analysis based on pipeline projects. *Human Vaccines & Immunotherapeutics*. 2015; *11*(12): 2769-2776. (SCI)
116. He TT, **Hu H\*,** Wang YT. Implementation status and barriers of good manufacturing practice (GMP) for Chinese patent medicine. *African Journal of Traditional, Complementary and Alternative Medicines*. 2015; 12(4): 56-64. (SCI)
117. He TT, Ung COL, **Hu H\*,** Wang YT. Good manufacturing practice (GMP) regulation of herbal medicine in comparative research: China GMP, cGMP, WHO-GMP, PIC/S and EU-GMP. *European Journal of Integrative Medicine.* 2015; 7(1): 55–66. (SCI)
118. **Hu H**, Chung CC\*. The innovation and modernisation of ‘herbal pieces’ in China: System evolution and policy transitions (1950s–2010s). *European Journal of Integrative Medicine*. 2015; 7(6): 645-649. (SCI)
119. **Hu H**, Chung CC.\* Biopharmaceutical innovation system in China: system evolution and policy transitions (Pre-1990s-2010s). *International Journal of Health Policy and Management*. 2015; 4(12): 823-829.
120. **Hu H**, Hafsi T. Entrepreneurial social capital and reciprocal dependence effects on strategy: An empirical study of CROs in China. *International Journal of Entrepreneurship and Small Business. 2015;* 24(2): 208-232.
121. **Hu H**\*, Zhang LM. Catch-Up of Chinese pharmaceutical firms facing technological complexity. *International Journal of Innovation and Technology Management*. 2015; 12(4): 1550017.
122. Lai YF, Lu JJ, **Hu H\***, Wang YT. Analysis of the current situation of antitumor drug use in China: a hospital-based perspective. *Therapeutic Innovation & Regulatory Science. 2015;* 49(1): 181-193. (SCI)
123. Li XW, Chen YN, Lai YF, Yang Q,\* **Hu H\***, Wang YT. Sustainable utilization of traditional Chinese medicine resources: systematic evaluation on different production modes. *Evidence-Based Complementary and Alternative Medicine*. 2015; 2015: 218901. (SCI)
124. Song M, Ung COL, **Hu H\***, Wang Y. Community pharmacists’ perceptions about pharmaceutical care of OTC western medicine: a survey in Harbin of China. *International Journal of Clinical Pharmacy*. 2015; 37(6): 1014-1020. (SCI)
125. Wu X, Si N, Bo G, **Hu H**, Yang J, Bian B, Zhao HY, Wang H. Characterization and quantitative amino acids analysis of analgesic peptides in cinobufacini injection by size exclusion chromatography, matrix‐assisted laser desorption/ionization time of flight mass spectrometry and gas chromatography mass spectrometry. *Biomedical Chromatography*. 2015; 29(1): 138-147. (SCI)
126. Xu FX, Yuan C, Wan JB, Yan R, **Hu H**, Li SP, Zhang QW. A novel strategy for rapid quantification of 20 (S)-protopanaxatriol and 20 (S)-protopanaxadiol saponins in Panax notoginseng P. ginseng and P. quinquefolium. *Natural Product Research*. 2015; 29(1): 46-52. (SCI)
127. Yu XW, **Hu H\***, Chen XP, Hu Y, Wang YT. Technology road mapping for innovation pathways of fibrates: a cross-database patent review. *Tropical Journal of Pharmaceutical Research*. 2015; 14(8): 1459-1467. (SCI)
128. Zhang MY, Li J, **Hu H\***, Wang Y. Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody (mAb) development in China. *Health Research Policy and System*. 2015; 13:64. (SSCI)
129. Zhang MY, Lu JJ, Wang L, Gao ZC, **Hu H\***, Ung COL, Wang YT. Development of monoclonal antibodies in China: overview and prospects. *BioMed Research International.* 2015; 2015: 168935. (SCI)
130. Duan GM, Qiu L, Yu WP, **Hu H\***. Outpatient service quality and doctor-patient relationship: a study in Chinese public hospital. *International Journal of Services, Economics and Management.* 2014; 6(1): 97-111.
131. Ge S, He TT, **Hu H\***. Popularity and customer preferences for over-the-counter Chinese medicines perceived by community pharmacists in Shanghai and Guangzhou: a questionnaire survey study. *Chinese Medicine.* 2014; 9: 22. (SCI)
132. Ma ZQ, **Hu H\*,** Zhang MY, He TT, Guo H, Chen MW, Wang YT. An assessment of traditional Uighur medicine in current Xinjiang region (China). *African Journal of Traditional, Complementary and Alternative Medicines.* 2014; 11(2): 301-314. (SCI).
133. He TT, **Hu H**, Wang YT. From low tech to modern industry: a study of traditional Chinese medicine sector in Guangdong, China. *Journal of Science & Technology Policy Management.* 2014; 5(3): 247-264.
134. Ng W, **Hu H\*.** From medicine to food: evolution of TCM health food sector in China. *International Journal of Transitions and Innovation Systems.* 2014; 3(4): 291-306.
135. Qiu L, Chen ZY, Lu DY, **Hu H\*,** Wang YT. Public funding and private investment for R&D: a survey in China’s pharmaceutical industry. *Health Research Policy and Systems.* 2014; 12: 27. (SSCI)
136. Qiu L, Yu YY, Liu JJ, **Hu H\*,** Wang YT. For-profit medical institutions in China: current status analysis and comparation with non-profit ones. *Journal of Pharmaceutical and Health Services Research. 2014;* 5(1): 37-47.
137. Shi YZ, **Hu H\***, Wang C. Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation. Globalization and Health. 2014; 10: 78. (SSCI)
138. Shi YZ, **Hu H\***, Wang YT. Technology uncertainty and technology sourcing: case study of biopharmaceuticals in China. *International Journal of Business Innovation and Research.* 2014; 8(5): 566-580.
139. Yu WP, Chen Y, Duan GM, **Hu H\***, Ma HS, Dai Y. Patients’ perceptions of day surgery: a survey study in China. *Hong Kong Medical Journal.* 2014; 20(2): 134-138. (SCI)
140. Yu YY, Ma ZQ, **Hu H\***, Wang YT. Local government policies and pharmaceutical clusters in China. *Journal of Science and Technology Policy Management*. 2014; 5(1): 41-58.
141. Zhang MY, Chong WK, **Hu H\*,** Wang YT. Pharmacy-perceived consumer preferences: a survey of community pharmacies in Macau. *Journal of Medical Marketing*. 2014; 14(1): 41–48.
142. Chao WC, **Hu H\*,** Ung COL, Cai Y. Benefits and challenges of electronic health record system on stakeholders: a qualitative study of outpatient physicians. *Journal of Medical Systems*. 2013; 37(4): 9960. (SCI)
143. Chen MW, Zhang JM, Lai YF, Wang SP, Li P, Xiao J, Fu CM, **Hu H,** Wang YT. Analysis of Pogostemon cablin from pharmaceutical research to market performances. *Expert Opinion on Investigational Drugs*. 2013; 22(2): 245-257. (SCI)
144. Chong WK, Chao WC, **Hu H\***, Cheng LJ. Responses of community pharmacies to rapidly rising competition: a survey study in Macao. *International Journal of Pharmaceutical Science and Health Care.* 2013; 3(3): 1-8.
145. Io UM, **Hu H\*,** Ung COL. Physicians’ and pharmacists’ experience and expectations of the roles of pharmacists: insights into hospital setting in Macao. *Tropical Journal of Pharmaceutical Research. 2013;* 12(6): 1077-1085. (SCI).
146. Shi HH, Chen MW, Shi YZ, **Hu H\*,** Wang YT. Challenges and prospects for monoclonal antibodies in China. *Journal of Commercial Biotechnology.* 2013; 19(2): 48-54.
147. Yu WP, Yu XW, **Hu H\***, Duan GM, Liu Z, Wang YT. Use of hospital appointment registration systems in China: a survey study. *Global Journal of Health Science.* 2013; 5(5): 193-201.
148. Zhang N, Liu JJ, **Hu H\*,** Wang YT. Cultural consideration in branding strategy of Chinese Patent Medicine: field study in Singapore, Guangzhou and Hong Kong. *Journal of Medical Marketing*. 2013; 13(3): 160-170.
149. Zhang LM, Lam WO, **Hu H\*.** Complex product and system, catch-up, and sectoral system of innovation: a case study of leading medical device companies in China. *International Journal of Technological Learning, Innovation and Development. 2013;* 6(3): 283-302*.*
150. Zhao HY, **Hu H\***, Wang YT. Comparative metabolism and stability of andrographolide in liver microsomes from humans, dogs and rats using ultraperformance liquid chromatography coupled with triplequadrupole and Fourier transform ion cyclotron resonance mass spectrometry. *Rapid Communication in Mass Spectromery*. 2013; 27(12): 1385-1392. (SCI)
151. Ge S, Cheong KL, **Hu H\*,** Wang YT. Provision and usage of medical services by community pharmacy: a comparative study of New York, Macao and Zhuhai (China). *Canadian Social Science*. 2013; 8(6): 11-17.
152. Lai YF, Lu JJ, Chen XP, **Hu H\*,** Wang YT. Analysis of anti-cancer traditional Chinese Medicine Injections based on market performance. *World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica*. 2012; 14(5): 1958-1962.
153. **Hu H\*,** Hafsi T. Strategic change in a shifting institutional context: east and west China. *Journal of Change Management.* 2010; 10(3): 293-313.

**6. Journal articles in Chinese (中文期刊发表)**

1. 陈圣琦， 宋佳芳， 史洪昊， 朱贺， 胡豪， 史录文， 韩晟. 慢性阻塞性肺疾病患者用药模式识别评价和医疗费用分析. 临床药物治疗杂志, 2020; 18:30-34.
2. 李蒙, 胡豪, 吴霭琳. 大数据在药物警戒中的应用研究进展. 中国药物警戒. 2020; 17(5): 311-314.
3. 时君楠， 梁钻姬， 赖云锋， 胡豪， 吴霭琳.发展和应用监管科学: 中国, 美国, 欧盟和日本的药品监管机构的经验. 中国食品药品监管, 2020; 5: 38-55.
4. 陈小兰, 陈圣琦, 史洪昊, 胡豪, 史录文, 韩晟. 基于医疗大数据的中国哮喘患者用药模式识别评价和医疗费用分析. 中国药物经济学. 2019; 14(5): 18-26.

Chen X, Chen S, Shi H, **Hu H**, Shi L, Han S. Identification and evaluation of medicine use pattern and medical cost analysis of asthma patients in China based on medical big data. *China Journal of Pharmaceutical Economics*. 2019; 14(5): 18-26.

1. 赖云锋, 陈献文, 陈圣琦, 郭琰, 别瑞雪, 韩晟, 史录文, 胡豪\*. 中国呼吸系统疾病药物利用现状：基于 3 个数据库比较分析. 中国药物经济学. 2019; 14(5): 18-26.

Lai Y, Chen X, Chen S, Guo Y, Bie R, Han S, Shi L, **Hu H\***. Current drug utilization of respiratory system disease in China: a comparative analysis based on 3 databases. *China Journal of Pharmaceutical Economics*. 2019; 14(1): 21-25.

1. 吴霭琳, 李兰婷, 胡豪\*. 使用基础胰岛素类似物治疗2型糖尿病患者低血糖发生率研究:基于中国4家三级甲等医院的真实数据.中国糖尿病杂志. 2019; 27(5): 331-336.

Wu A, Li L, **Hu H\***. Rate of hypoglycemic events in type 2 diabetes patients using basal insulin analogues: a real-world analysis of four grade Ш class A hospitals in China. Chinese Journal of Diabetes. 2019; 27(5): 331-336.

1. 史洪昊, 蔡颖怡, 卞鹰, 胡豪\*. 商业健康保险与高成本药品的可负担性: 典型模式的对比分析. *保险理论与实践*. 2018; 9: 120-130.

Shi H, Choi WI, Bian Y, **Hu H\***. Commercial health insurance and affordability of high-cost drug. *Insurance Practice & Theory*. 2018; 9: 120-130.

1. 蔡勇, 李西文, 倪静云, 程努华, 陈海, 王一涛, **胡豪\***. 基于二维码的中药质量可追溯系统. *中药材*. 2016; 2: 275-280.

Cai Y, Li X, Ni J, Cheng N, Chen H, Wang YT, **Hu H\***. Quality traceability system of TCM based on two-dimensional code. *Journal of Chinese Medicinal Materials*. 2016; 2: 275-280.

1. 陈虹, 胡豪\*. 银川市居民购买非处方药品时对社区药房药师提供药学服务感知的调查. *中国药房*. 2016; *27*(30): 4197-4199.

Chen H, **Hu H**\*. Investigation of residents’ perceptions for pharmaceutical care when purchasing OTC drugs in Yinchuan. *China Pharmacy*. 2016; *27*(30): 4197-4199.

1. 索思卓, **胡豪\***, 王一涛. 特殊医学用途配方食品在中国的发展概况. *中国食品卫生杂志*. 2016; *28*(2): 182-186.

Suo S, **Hu H\***, Wang YT. Development of foods for special medical purposes in China: from the perspective of sectoral innovation system. *Chinese Journal of Food Hygiene*. 2016; *28*(2): 182-186.

1. 卢雅倩, 胡豪, 王一涛. 中药政策发展及影响分析. *中国卫生事业管理*. 2015; *32*(10): 766-768.

Lu Y, **Hu H\***, Wang YT. Analysis of the development and effect of Chinese Materia Medica policies. *Chinese Health Service Management*. 2015; *32*(10): 766-768.

1. 王苡蕙, 胡豪, **王一涛\***.台湾地区健康食品产业发展: 基于产品登记和审核的分析. *中国现代中药.* 2015; 17(6): 604-607.

Wang Y, **Hu H**, Wang YT\*. Development of health food industry in Taiwan: an analysis based on product registry and product approval. *Modern Chinese Medicine.* 2015; 17(6): 604-607.

1. 蔡勇, 陈宇宁, **胡豪**\*, 倪静云. 一种中医药行业网络资源共享架构. 世界科学技术—中医药现代化. 2013; 8: 1853-1859.

Cai Y, Chen YN, **Hu H**\*, Ni JY. One network resource sharing architecture of traditional Chinese medicine industry. *World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica*. 2013; 8: 1853-1859.

1. 蔡勇, **胡豪**\*, 倪静云, 王一涛. 中药质量追溯体系发展现状研究. 中国中药杂志. 2013; 38(22): 3829-3833.

Cai Y, **Hu H\***, Ni JY, Wang YT. Development of quality traceability system of traditional Chinese medicine. *China Journal of Chinese Materia Medica*. 2013; 38(22): 3829-3833.

1. 蔡勇, 刘美玲, **胡豪\***, 石韻臻. Ruby On Rails 在中医药数据共享平台的应用. 计算机系统应用. 2013; 22(7): 63-67.

Cai Y, Liu ML, **Hu H\***, Shi YZ. Ruby on rails applied in TCM data sharing platform. *Computer Systems and Applications*. 2013; 22(7): 63-67.

1. 蔡勇, 刘美玲, 李玫, **胡豪\***. 一种中医药行业搜索引擎的推荐词产生方式. 计算机系统应用. 2013; 22(5): 151-154.

Cai Y, Liu ML, Li M, Hu H. A method to generate query recommendations for search engine of the Traditional Chinese Medicine industry. *Computer Systems and Applications*. 2013; 22(5): 151-154.

1. 蔡勇, 郑平, 张楠, 胡豪. 2013. 粤澳中医药科技产业园智能物流中心的规划与设计. 物流技术, 32(10): 136-139. (Percentage of contribution: 15%; Chinese Core Journal)

Cai, Y., Zheng, P., Zhang, N., & Hu, H. 2013. Programming and design of Guangdong-Macau Chinese Medicince Technology Industrial Park. *Logistics Technology*, 32(10): 136-139.

1. 符永钰, 于小文, 于元元, 胡豪. 2013. 基于商业模式视角的化学药企业技术创新和产业追赶. 科技管理研究, 15: 5-8.

Fu, Y. Y., Yu, X.W., Yu, Y. Y., & Hu, H. 2013. Technical innovation and industry catch-up of chemical medicine enterprise under the perspective of business model. *Science and Technology Management Research*, 15: 5-8.

1. 胡豪, 张黎明. 2013. B2B企业如何玩转消费市场.中欧商业评论, 3: 46-49. (Percentage of contribution: 70%)

Hu, H., & Zhang, L. M. 2013. How B2B companies enter into consumer market. *CEIBS Business Review*, 3: 46-49.

1. 张君隆, 于小文, 胡豪, 王一涛. 2013. 美国纽约、中国澳门和中国珠海社区药房基础服务的对比分析. 药学服务与研究, 13(2): 143-146. (Percentage of contribution: 25%; Chinese Core Journal)

Cheong, K. L., Yu, X. W., Hu, H., & Wang, Y. T. 2013. Comparison of basic service by community pharmacies in New York of USA, Macao and Zhuhai of China. *Pharmaceutical Care and Research*, 13(2): 143-146.

1. 马志桥, 章懋妤, 胡豪, 王一涛. 2013. 新疆维吾尔药成药研究进展——基于专利申请与学术文献分析, 中国民族民间医药, 22(15):4-7. (Percentage of contribution: 25%; Chinese Core Journal)

Ma, Z. Q, Zhang, M. Y, Hu, H., & Wang, Y.T. 2013.Advances of Uighur Patent Medicine in Xinjiang: Based on Patent Applications and Academic Publications. *Chinese Journal of Ethnomedicine and Ethnopharmacy Research*, 22(15):4-7.

1. 马志桥, 章懋妤, 陈美婉, 胡豪, 王一涛. 2013. 新疆维吾尔药材研究概况: 基于专利申请与学术发表, 中国民族民间医药, 36(12):2071-2074. (Percentage of contribution: 25%; Chinese Core Journal)

Ma, Z. Q, Zhang, M. Y, Chen, M.W., Hu, H., & Wang, Y.T. 2013. Advances of Uighur herbs in Xinjiang: Based on Patent Applications and Academic Publications. Journal of Chinese Medicinal Materials, 36(12):2071-2074.

1. 马志桥, 于元元, 胡豪, 王一涛. 2013. 基于结构视角下的中国制药产业集群中的政府行为.科技管理研究, 14:40-44. (Percentage of contribution: 25%; Chinese Core Journal)

Ma, Z. Q., Yu, Y. Y., Hu, H., & Wang, Y. T. 2013. Government actions of Chinese pharmaceutical industry clusters in view of local policy. *Science and Technology Management Research*, 14:40-44.

1. 于小文, 张秀婷, 胡豪, 王一涛. 2013. 基于授权专利分析的美欧中贝特类药物技术分析及预测. 情报杂志, 4:54-58. (Percentage of contribution: 25%; Chinese Core Journal)

Yu, X. W., Zhang, X. T., Hu, H., & Wang, Y. T. 2012. Technological analysis and forecasting of Fibrates Base on Patent Analysis between America, Europe and China. *Journal of Intelligence*, (accepted).

1. 张黎明, 胡豪, 石韵臻. 2013. 中国制药企业的追赶: 技术复杂性与部门创新. 四川大学学报( 哲学社会科学版), 6: 98-107. (Percentage of contribution: 25%; Chinese Core Journal)

Zhang, L.M., Hu, H., & Shi, Y.Z. 2013. A study on the catch-up strategy of Chinese pharmaceutical firms: Technical complexity and sectoral innovation. *Journal of Sichuan University ( Social Science Edition)*, 6: 98-107..

1. 赖云锋, 胡豪. 2012. 基于网络能力视角的制药企业研发创新演进. 科技管理研究, 7: 9-12. (Percentage of contribution: 45%; Chinese Core Journal)

Lai, Y. F. & Hu, H. 2012. R&D innovation evolution of pharmaceutical companies from the perspective of network competence. *Science and Technology Management Research*, 7: 9-12.

1. 史洪昊, 胡豪，王一涛. 2012. 竞合视角下的中国医药企业间合作. 科技管理研究, 5: 116-123. (Percentage of contribution: 35%; Chinese Core Journal)

Shi, H, H., Hu, H., & Wang, Y.T. 2012. Analysis on cooperation between pharmaceutical companies in China from the perspective of competition and cooperation theory. *Science and Technology Management Research*, 5: 116-123.

1. 史洪昊, 胡豪, 王一涛.2012. 从商业模式探究中国单抗产品的发展路径.科技管理研究, 21: 111-114. (Percentage of contribution: 35%; Chinese Core Journal)

Shi, H. H., Hu, H., & Wang, Y. T. 2012. Probe into the development path of China monoclonal antibody products from business model. *Science and Technology Management Research*, 21: 111-114.

1. 石韵臻, 胡豪, 王一涛. 2012. 自主研发还是外部获取？中国生物制药商业模式的技术考量. 管理案例研究与评论, 5(3): 205-212. (Percentage of contribution: 35%)

Shi, Y. Z., Hu, H., & Wang, Y. T. 2012. Independent R&D or external acquisition? Technical considerations for the business model of Chinese biopharmaceuticals. *Journal of Management Case Studies*, 3(1): 26-33.

1. 于小文, 符永钰, 胡豪, 王一涛. 2012. 商业模式视角下的中成药产品创新选择. 中国医药技术经济与管理, 4:54-58. (Percentage of contribution: 25%)

Yu, X. W., Fu, Y. Y., Hu, H., & Wang, Y. T. 2012. Innovation choice of Chinese Patent Medicine from the perspective of business model. *Chinese Journal of Pharmaceutical Technology Economics and Management*, 4:54-58.

1. [张君隆](http://www.cnki.net/KCMS/detail/search.aspx?dbcode=CJFQ&sfield=au&skey=%e5%bc%a0%e5%90%9b%e9%9a%86&code=26970911;28339206;17394552;26324050;), [符永钰](http://www.cnki.net/KCMS/detail/search.aspx?dbcode=CJFQ&sfield=au&skey=%e7%ac%a6%e6%b0%b8%e9%92%b0&code=26970911;28339206;17394552;26324050;), [胡豪](http://www.cnki.net/KCMS/detail/search.aspx?dbcode=CJFQ&sfield=au&skey=%e8%83%a1%e8%b1%aa&code=26970911;28339206;17394552;26324050;), [梁少伟](http://www.cnki.net/KCMS/detail/search.aspx?dbcode=CJFQ&sfield=au&skey=%e6%a2%81%e5%b0%91%e4%bc%9f&code=26970911;28339206;17394552;26324050;). 2012. 美国纽约中国澳门和珠海社区药房药学服务的对比分析. 医药导报, 31(12):1663-1665 . (Percentage of contribution: 25%; Chinese Core Journal)

Cheong, K. L., Fu, Y. Y., Hu, H., & Leung, S.W. 2012. Comparison of pharmaceutical service by community pharmacies in New York of USA, Macao and Zhuhai of China. *Hearld of Medicine*, 31(12):1663-1665.

1. 张君隆, 葛帅, 胡豪, 王一涛. 2012. 珠海、澳门和纽约社区药房医学服务的对比研究. 中国医药导报, 9(27): 129-131. (Percentage of contribution: 25%)

Cheong, K. L., Ge, S., Hu, H., & Wang, Y. T. 2012. Comparative study of medical service of community pharmacy in Zhuhai, Macao and New York. *China Medical Hearld*, 9(27): 129-131.

1. 张君隆, 胡豪. 2012. 澳门药房的服务提升, 以美国药房为对比借鉴. 亚洲社会医学, 7(2): 128-130. (Percentage of contribution: 45%)

Cheong, K. L., & Hu, H. 2012. Enhancing Macau pharmacy services: With references to U.S. pharmacies. *Asian Journal of Social Pharmacy*, 7(2): 128-130.

1. 张露, 胡豪. 2012. 中药饮片药典标准的建立情况简析.中国中医药咨讯, 4(3): 4-5. (Percentage of contribution: 45%)

Zhang, L., & Hu, H. 2012. The establishment of Chinese herbal medicine Pharmacopoeia standards. *Journal of China Traditional Chinese Medicine Information*, 4(3): 4-5.

1. 张露, 胡豪. 2012. 复杂产品系统视角下的医药研发: 新药研发的技术复杂性分析与项目分解. 科技进步与对策, 15: 8-12. (Percentage of contribution: 35%; Chinese Core Journal)

Zhang, L., & Hu, H. 2012. Pharmaceutical R&D in the perspective of CoPS: Technology complexity analysis and project division in new drug development. *Science & Technology Progress and Policy*, 29(15): 8-12.

1. 赵扬, 胡豪, 王一涛. 2011. 基于发展中国家相关案例探索我国制药企业产业升级的突破路径. 中国药房, 22(33): 3076-3078. (Percentage of contribution: 35%; Chinese Core Journal)

Zhao, Y., Hu, H., & Wang, Y. T. 2011. Approaches for industry upgrade of Chinese pharmaceutical enterprises based on relevant cases from developing countries. *China Pharmacy*, 22(33): 3076-3078.

1. 张君隆, 胡豪. 2011. 澳门药品供应链上的批发商与药房: 职能分工和关系争议. 澳门理工学报, 14(2): 155-164. (Percentage of contribution: 45%)

Cheong, K. L. & Hu, H. 2011. Wholesale distributors and pharmacies in the pharmaceutical supply chain of Macau: Division of functions and relationship conflicts. *Journal of Macao Polytechnic Institute*, 14(2): 155-164.

1. 高华, 胡豪. 2011. 中国医学超声仪器企业的追赶战略.科技管理研究, 31(10): 39-42. (Percentage of contribution: 35%; Chinese Core Journal)

Gao, H., & Hu, H. 2011. Latecomer catch-up strategies in Chinese ultrasonic equipment companies. *Science and Technology Management Research*, 31(11): 39-42.

1. 鲍菲飞, 胡豪. 2011. 从本土代理商到国际竞争者：深圳迈瑞医疗的经验与启示. 企业活力, 5: 30-34. (Percentage of contribution:35%; Chinese Core Journal)

Bao, F. F, & Hu, H. 2011. From local agent to international competitor: Experience and implication of Shenzhen Mindray. *Enterprise Vitality*, 5: 30-34.

1. 胡豪, 杨沁心, 张黎明. 2011. 公司品牌锋芒初露. 管理学家, 1: 90-93. (Percentage of contribution: 55%)

Hu, H., Yang, Q. X., & Zhang, L. M. 2011. The emergence of corporate brand. *Management Scholar*, 1: 90-93.

1. 张黎明, 胡豪. 2011. 技术能力在企业战略导向选择中的作用机制研究. 四川大学学报(哲学社会科学版), 1: 110-115. (Percentage of contribution: 25%; Citation=3; Chinese Core Journal)

Zhang, L. M., & Hu, H. 2011. The Functional mechanism of technology ability in enterprise strategy oriented selection. *Journal of Sichuan University (Social Science Edition)*, 1:110-115.

1. 张黎明, 杨沁心, 胡豪. 2011. 以战略行动推动新创企业公司品牌构筑: 以四川嘉熙实业有限公司及谭鱼头股份有限公司个案比对为例. 管理案例研究与评论, 4(2): 112-120. (Percentage of contribution: 25%)

Zhang, L. M., Yang, Q. X., & Hu, H. 2011. Promote corporate brand building for newly established businesses through strategic action based on the comparative case studies of Sichuan Jiaxi Industrial Co., Ltd. and Tanyutou Co., Ltd. *Journal of Management Case Studies*, 4(2): 112-120.

1. [胡豪](http://readopac1.ncl.edu.tw/nclJournal/search/search_result.jsp?la=ch%E5%9C%8B%E5%AE%B6%E5%9C%96%E6%9B%B8%E9%A4%A8&search_type=adv&dtdId=000040&sort_index=PD&sort_type=1&search_index=AU&search_mode=&search_value=%E8%83%A1%E8%B1%AA+Hu%2C+Hao+$), [賴雲鋒](http://readopac1.ncl.edu.tw/nclJournal/search/search_result.jsp?la=ch%E5%9C%8B%E5%AE%B6%E5%9C%96%E6%9B%B8%E9%A4%A8&search_type=adv&dtdId=000040&sort_index=PD&sort_type=1&search_index=AU&search_mode=&search_value=%E8%B3%B4%E9%9B%B2%E9%8B%92+Lai%2C+Yunfeng+$). 2011. 互動中的健康事業：鏡湖醫院與澳門社群. Health Service in Interaction: Kiang Wu Hospital and Macau Society. [澳門研究](http://readopac1.ncl.edu.tw/nclJournal/search/guide/search_result.jsp?dtdId=000075&search_index=JT&search_mode=&search_value=%E6%BE%B3%E9%96%80%E7%A0%94%E7%A9%B6$&la=ch&requery=true), 62: 44-49. (Percentage of contribution: 25%)

Hu, H., & Lai, Y. F. 2011. Health Service in Interaction: Kiang Wu Hospital and Macau Society. *Journal of Macau Studies*, 62: 44-49.

1. 余文心, 胡豪，史录文, 王一涛. 2010. 中国研发导向型制药企业外部资源整合行为探究.科技进步与对策, 28(4): 85-89. (Percentage of contribution: 25%; Chinese Core Journal)

Yu, W. X., Hu, H., Shi, L. W., & Wang, Y. T. 2010. Research on the behaviour of integrating external resource in the R&D oriented pharmaceutical companies of China. *Science & Technology Progress and Policy*, 28(4): 85-89.

1. 张黎明, 胡豪. 2010. 公司品牌引领企业战略选择. 管理学家, 3: 33-37. (Percentage of contribution: 55%)

Zhang, L. M., & Hu, H. 2010. Use corporate brand to lead strategic choice. *Management Scholar*, 3: 33-37.

1. 范妙璇, 胡豪, 赵海誉, 王一涛. 2010. 中国医药研发外包行业竞争优势研究.中国科技论坛, 5:36-40. (Percentage of contribution: 25%; Chinese Core Journal; Citation=1)

Fan, M. X., Hu, H., Zhao, H. Y., & Wang, Y. T. 2010. Study on the Competitive Advantage of Contract Research Organizations in China. *Forum on Science & Technology in China*, 5: 36-40.

1. 冯雪敏, 胡豪, 王一涛. 2010.集团体制下的业务组合构建及其管控. 中国经贸导刊, 19: 62. (Percentage of contribution: 25%)

Feng, X. M., Hu, H., & Wang, Y. T. 2010. Design and control of business portfolio in business group. *China Economy and Trade Management*, 19: 62.

1. 冯雪敏, 胡豪. 2010. 企业集团体制下的品牌构建. 经济研究导刊, 30: 17-19. (Percentage of contribution: 25%; Chinese Core Journal)

Feng, X. M., & Hu, H. 2010. Construction of corporate brand under business group system. *Economic Research Guide*, 30:17-19.

1. 耿向楠, 胡豪, 史录文, 王一涛. 2010. 药物经济学循证方法浅析. 中国药物经济学, 4:39-45. (Percentage of contribution: 25%; Citation=1)

Geng, X. N., Hu, H., & Wang, Y. T. 2010. An analysis of evidence-based pharmaceutical economic evaluation. *China Journal of Pharmaceutical Economics*, 4: 39-45.

1. 胡豪, 范妙璇, 王一涛. 2010. 中国CRO企业产业价值链定位与制药产业创新能力.中国医药技术经济与管理, 4(5): 64-67. (Percentage of contribution: 45%)

Hu, H., Fan, M. X., & Wang, Y. T. 2010. CROs positioning in industrial value chain and innovation capabilities of pharmaceutical industry in China. *Chinese Journal of Pharmaceutical Technology Economics and Management*, 4(5): 64-67.

1. 胡豪, 范妙璇, 余文心. 2010. 商业CRO与制药客户的权力动态与信任战略.管理案例研究与评论, 3(1):26-33. (Percentage of contribution: 25%; Citation=1)

Hu, Hao., Fan, M. X. & Yu, W. X. 2010. Power dynamics and trust strategy between CROs and their pharmaceutical clients*. Journal of Management Case Studies*, 3(1): 26-33.

1. 黄振华, 胡豪, 王一涛. 2010. 跨国药企在华技术溢出的途径分析. 生产力研究, 8: 125-126. (Percentage of contribution: 25%; Chinese Core Journal; Citation=1)

Huang, Z. H., Hu, H., & Wang, Y. T. 2010. Analysis of technological spillover of pharmaceutical MNCs in China. *Productivity Research*, 8: 125-126.

1. 彭学韬, 胡豪,王一涛. 2010. 品牌管理策略：王老吉品牌成功的原因. 企业活力, 3: 28-32. (Percentage of contribution: 25%; Chinese Core Journal; Citation=2)

Peng, X. T., Hu, H., & Wang, Y. T. 2010. Brand management strategy: The reasons for the success of “Wong Lo Kat”. *Enterprise Vitality*, 8:23-27.

1. 彭雪韬, 胡豪, 王一涛. 2010. 中药企业创新路径选择: 以香港维特健灵和培力为借鉴.特区经济, 5: 287-289. (Percentage of contribution: 25%; Chinese Core Journal)

Peng, X. T., Hu, H., & Wang, Y. T. 2010. Innovation path of Chinese medicine enterprises. *Special Zone Economy*, 5:287-289.

1. 彭雪韬, 胡豪, 王一涛. 2010. 中药企业创新系统构建: 以香港培力为案例.企业活力, 8: 23-27. (Percentage of contribution: 25%; Chinese Core Journal)

Peng, X. T., Hu, H., & Wang, Y. T. 2010. TCM enterprise innovation system construction: Experience of Pura Pharm. *Enterprise Vitality*, 8:23-27.

1. 苏伟萍，胡豪，史录文，王一涛. 2011. 制药行业me too药的自主开发策略.中国新药杂志, 19(11):926-929. (Percentage of contribution: 25%; Chinese Core Journal)

Su, W. P., Hu, H., Shi, L. W., & Wang, Y. T. 2010.Development and marketing strategies of me too drug. *Chinese Journal of New Drugs*, 19 (11): 926-929.

1. 宿莹莹, 胡豪. 2010. 中国上市制药公司首募资金投向变更的实证研究. 经济研究导刊, 36: 68-71. (Percentage of contribution: 25%; Chinese Core Journal; Citation=2)

Su, Y. Y. & Hu, H. 2010. Empirical study of investment change of IPO funding of public pharmaceutical companies in China. *Economic Research Guide*, 36: 68-71.

1. 宿莹莹, 胡豪. 2010. 珠澳药店研究及我国药店连锁式多元化发展. 中国商贸, 7-8. (Percentage of contribution: 25%)

Su, Y. Y. & Hu, H. 2010. Research on community pharmacies in Zhuhai & Macau: Implications for franchising pharmacies. *China Business Trade*, 16: 7-8.

1. 张黎明, 胡豪. 2010. 新产品研发能力对企业战略导向的影响实证分析.经济问题, 7:63-66. (Percentage of contribution: 35%; Chinese Core Journal; Citation=3)

Zhang, L. M., & Hu, H. 2010. Empirical study of the impact of R&D capability on strategic orientation of firms. *On Economic Problems*, 7:63-66.

1. 黄海红, 胡豪. 2009. 澳门药物批发供应商的产业定位及市场行为分析.澳门研究, 55: 149-154. (Percentage of contribution: 45%)

Wong, H. H. & Hu, H. 2009. Industrial position and market behavior of pharmaceutical wholesalers in Macau. *Journal of Macau Studies*, 55:149-154.

1. 范妙璇, 胡豪, 赵海誉, 王一涛. 2009. 提高中国医药科技国际竞争力途径——中国医药行业研发联盟现状研究. 中国医药技术经济与管理, 3(5): 38-45. (Percentage of contribution: 35%; Citation = 6)

Fan, M. X., Hu, H., Zhao, H. Y., & Wang, Y. T. 2009. The way of increase competitive strength on medical and pharmaceuticals sciences in international market: The study of current situation on Chinese R&D alliances. *Chinese Journal of Pharmaceutical Technology Economics and Management*, 3(5):38-45.

1. 冯雪敏, 胡豪. 2009. 建立药品创新与现实市场间的联接——动态模拟在新药产品战略中的应用. 中国药物经济学, 4: 63-68. (Percentage of contribution: 25%)

Feng, X. M. & Hu, H. 2009. Build link between pharmaceutical innovation and realistic market: Application of dynamic modeling in pharmaceutical product Strategy. *China Journal of Pharmaceutical Economics*, 4: 63-68.

1. 彭学韬, 胡豪,王一涛. 2009. 跨国制药企业在华研发投入机制研究.中国药业, 18(16): 13-14. (Percentage of contribution: 35%; Chinese Core Journal; Citation=3)

Peng, X. T., Hu, H., & Wang, Y. T. 2009. Research on R&D investment mechanism of multinational pharms in China. *China Pharmaceuticals*, 18(16):13-14.

1. 谢元昊, 胡豪, 谭睿, 王一涛. 2009. 基因工程与中药药效评价.中国天然药物, 7(6): 476-480. (Percentage of contribution: 35%; Chinese Core Journal; Citation=1)

Xie, Y. H., Hu, H., Tan, R., & Wang, Y. T. 2009. Genetic Engineering Technology and Pharmacological Evaluation of Chinese Medicine. *Chinese Journal of Natural Medicine*, 7(6):476-480.

1. 黄洲萍, 王一涛, 胡豪, 胡元佳, 孙良堃. 2008. 澳门中医药科技与产业发展研究.世界科学技术-中药现代化, 10(2): 112-115. (Percentage of contribution: 10%; Chinese Core Journal)

Huang, Z. P., Wang, Y. T., Hu, H., Hu, Y. J., & Sun, L. K. 2008. Prospect of TCM development in Macau. *World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica*, 10(2):112-115.

1. 秦佑鹏, 胡豪, 王一涛. 2008. 中药企业国际化策略案例研究.中国医药工业, 39(11): 874-876. (Percentage of contribution: 25%; Chinese Core Journal; Citation = 4)

Qin, Y. P., Hu, H., & Wang, Y. T. 2008. Case comparison on internationalization strategies of traditional Chinese Medicine enterprises. *Chinese Journal of Pharmaceuticals*, 39(11):874-876.

1. 孙良堃, 胡豪, 王一涛. 2008. 互联网对处方药宣传的平台作用研究.中国药业, 17(16): 11-12. (Percentage of contribution: 25%; Chinese Core Journal; Citation = 1)

Sun, L. K., Hu, H., & Wang, Y. T. 2008. Research on Internet as platform of promoting prescription drugs. *China Pharmaceuticals*, 17(16):11-12.

1. 张珵, 胡豪, 王一涛. 2008. 医药传媒的特征、作用及其发展策略初探.中国卫生事业管理, 7: 497-499. (Percentage of contribution: 25%; Citation = 1)

Zhang, C., Hu, H., & Wang, Y.T. 2008. Surveying the characteristic, action and developing strategy of medical media. *Chinese Health Service Management*, 7:497-499.

**7. Books(书籍)**

1. 陈维政, 刘苹, 胡豪. 2018. 人力资本管理. 北京：高等教育出版社.

Chen W, Liu P, Hu H. 2018. Human Capital Management. Beijing: Higher Education Press.

1. Leung SW, **Hu H**. 2017. *Evidence-based Research Methods for Chinese Medicine*. Singapore: Springer.
2. 胡豪, 张黎明. 2014. 重塑价值逻辑：中国制药产业的业务模式创新. 北京: 清华大学出版社.

**Hu H**, Zhang LM. 2014. *Rebuild Value Logics: Business Model Innovation in the Chinese Pharmaceutical Industry*. Beijing: Tsinghua University Press*.*

1. 胡豪, 陈维政, 刘苹. 2011. 权变公司治理模式研究. 成都: 四川大学出版社.

**Hu H**, Chen W, Liu P. 2011. *Contingency Model of Corporate Governance*. Chengdu: Sichuan University Press.

1. 张黎明, 胡豪. 2011. 公司品牌的战略选择. 北京: 清华大学出版社.

Zhang LM, **Hu H**. 2011. *Strategic Choice of Corporate Brand*. Beijing: Tsinghua University.

1. 李后钧, 胡豪. 2010. 人力资源战略管理:制度环境管理与核心竞争力塑造的视角. 北京: 清华大学出版社/北方交通大学出版社.

Lee J, **Hu H\***. 2010. *Human Resource Strategy Management: A Combination Perspective of Institutional Environment and Core Competence*. Beijing: Tsinghua University and Beifang Jiaotong University Press.

1. 陈维政, 刘苹, **胡豪**. 2005. 人力资本与公司治理. 大连:大连理工大学出版社.

Chen W, Liu P, **Hu H**. 2005. Human Capital and Corporate Governance. Dalian: Dalian University of Technology Press.

**8. Book Chapters**

1. Hu H, Zhang L. Exploring technological complexity in the pharmaceutical industry. In Daim TU, Brem M (eds) *Managing Medical Technological Innovations*. Singapore: World Scientific. 2020.219-248.
2. Ung COL, Zheng T, Yao D, Harnett J, **Hu H\***. 2018.将补充药物纳入药师服务范围：澳大利亚的经验与启示. 中国执业药师发展报告(2017).33-39.
3. Hu H, Yao D, Ung COL. 2017.台灣地區藥師制度概述. 中国执业药师发展报告(2016).p.132-136.
4. Hu H, Yao D, Ung COL. 2017.香港藥劑師制度概述. 中国执业药师发展报告(2016).p.127-131.
5. Ni JY, Zhao JR, Ung COL, **Hu H**, Hu Y, Wang YT. 2017. Obstacles and opportunities in Chinese pharmaceutical innovation. Innovation Value Chain of Chinese Pharmaceuticals. United States-China Intellectual Property Institute Inc.pp.9-30.
6. Ung COL, Yao D, **Hu H\***. 2016. 澳门特别行政区药剂师的发展与现状. 中国执业药师发展报告(2015).121-131.
7. **Hu H**, Li J, Chen H. 2016. Qualitative interview for Chinese medicine research: Challenges and prospects. *Evidence-based Research Methods for Chinese Medicine*.65-77.
8. Yuen SC, **Hu H**, Leung SW. 2016. Introduction. In *Evidence-based Research Methods for Chinese Medicine*.p.65-77.
9. Gao Z, Li J, **Hu H\***, Wang Y. 2016 Internationalization of Chinese pharmaceutical firms: Strategies and drivers. In Patricia Ordóñez de Pablos  (Eds). *Managerial Strategies and Practice in the Asian Business Sector*. IGI Global. p.150-168.
10. Yu WP, **Hu H\***. 2014. Corporate social responsibility in shaping corporate image: An empirical study of state-owned enterprises in China. In, Low [PKC](http://www.amazon.com/s/ref=ntt_athr_dp_sr_1?_encoding=UTF8&field-author=Patrick%20Kim%20Cheng%20Low&search-alias=books&sort=relevancerank), Idowu [SO,](http://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Samuel%20O.%20Idowu&search-alias=books&sort=relevancerank) Ang [SL](http://www.amazon.com/s/ref=ntt_athr_dp_sr_3?_encoding=UTF8&field-author=Sik%20Liong%20Ang&search-alias=books&sort=relevancerank). (eds). *Corporate Social Responsibility in Asia: Practice and Experience*. Springer.p.3-18.
11. **Hu H**. & Lévesque, C. 2011. The role of MNCs in reshaping employment relations in China. In Blackett A, Lévesque C (eds). *Social Regionalism in the Global Economy.* New York: Routledge.
12. 胡豪\*. 2009. 制度變革與區域競爭力提升：港澳回歸與珠三角中藥產業發展. 李思名, 黃枝連, 馮氏惠, 陳東林 (eds). 巨龍的甦醒: 中國改革開放三十年、港澳回歸、與東亞發展新範式. 澳門: 澳門大學出版社.

**Hu H\***. 2009. Institutional change and regional competence: Return of HK and Macao and TCM industrial development of Pearl River area. In Li, S. M. et al (eds). *The Wake-Up of Dragon*, Macau: University of Macau Press.

1. 于元元, 赖云锋, 于小文, 章懋妤, 郭宏, 卢雅倩, 陈宇宁, 胡豪. 2013. 医药产业园区与产业发展:理论与实践. 朱恒鹏(eds).中国中医药产业园发展战略蓝皮书.北京:中国社会科学文献出版社.

Yu, Y., Lai, Y. F., Yu, X. W., Zhang, M. Y., Guo, H., Lu, Y. Q., Chen, Y. N., & **Hu, H**\*. 2013. Medical industrial park and industry development: Theory and practice. In Zhu, H. P. (eds), *Blue Book of Development Strategy of TCM Industrial Parks in China*. Beijing: Social Science Academic Press (China).

1. 赖云锋, 马志桥, 章懋妤, 郭宏, 贺天天, 张秀婷, 陈宇宁, 胡豪. 2013. 中医药产业园区发展情况研究. 朱恒鹏(eds).中国中医药产业园发展战略蓝皮书.北京:中国社会科学文献出版社.

Lai, Y. F., Ma, Z. Q., Zhang, M. Y., Guo, H., He, T. T., Zhang, X. T., Chen, Y. N., & **Hu, H\***. 2013. Development of industrial parks of Traditional Chinese Medicine. In Zhu, H. P. (eds), *Blue Book of Development Strategy of TCM Industrial Parks in China*. Beijing: Social Science Academic Press (China).

1. 于元元, 于小文, 赖云锋, 马志桥, 张秀婷, 卢雅倩, 贺天天, 胡豪. 2013. 中医药产业园区的政策设计. 见: 裴长洪, 房书亭, 吴涤心等编. *医药蓝皮书-中国中医药产业园战略发展报告.* 北京: 社会科学文献出版社.

Yu, Y., Yu, X. W., Lai, Y. F., Ma, Z. Q., Zhang, X. T., Lu, Y. Q., He, T. T., & **Hu, H\***. 2013. Policy design for industrial parks of Traditional Chinese Medicine in China. In Zhu, H. P. (eds), *Blue Book of Development Strategy of TCM Industrial Parks in China*. Beijing: Social Science Academic Press (China).

**9. Conference papers**

1. Zou H, Xue Y, Chen X, Lai Y, Yao D, Ung COL, Hu H\*. Disease decision modelling for evaluating systemic therapies in advanced hepatocellular carcinoma: a comparative investigation. The Ninth Macau Symposium on Biomedical Sciences 2023; Macau SAR, China, 2023.
2. Zhen R, Ung CO, Hu H. PDG9 Economic impact of cardiovascular benefit of once-weekly semaglutide in type 2 diabetes patients with high cardiovascular risk in China. Value in Health. 2021;24:S88.
3. Zhen R, Shi H, Yang L, Hu H. PDB28 MODEL-Based LONG-TERM Cost-Effectiveness of Once-Weekly Semaglutide Compared with Other GLP-1 Receptor Agonists in Type 2 Diabetes: A Systematic Literature Review. Value in Health. 2020 Dec 1;23:S510.
4. Cai Y, GE Y, Ung COL, Li F, Wang J, Xia C, **Hu H**\*. PMU3 Medical cost for children with infantile hemangiomas in Southern China: investigation based on medical record data. *Value in Health Regional Issues*. 2020; 22: S68-9.
5. Lai YF, Chen XW, Chen SQ, Chen PH, Ung COL, **Hu H\***. PRS48 Drug utilization of patients with respiratory disease at community pharmacy in China: an analysis of leading prescription and over-the-counter drugs. *Value in Health*. 2019; 22: S358.
6. Lai Y, Chen SQ, Chen PH, Chen XW, Ung COL, **Hu H\***. PDG74 Drug utilization of patients with respiratory disease at community pharmacies in China: an analysis of chemical drugs (2014-2017). *Value in Health*. 2019; 22: S175.
7. Shi H, Guo WJ, Zhu H, Li M, Ung COL, **Hu H\***, Han S. PRS65 Effect and cost of traditional Chinese medicine *Xiyanping* injection for treating community acquired pneumonia among adults in China. *Value in Health*. 2019; 22: S361.
8. Ung COL, Harnett J, Hu H. P130 Development of a strategic model for integrating complementary medicines into professional pharmacy practice. *Advances in Integrative Medicine*. 2019; 6(S1): S96.
9. Ung COL, Li J, Zhu J, **Hu H**, Harnett J, Lei CI, Chau KY, Chan G. P029 Internationalization of Traditional/Complementary Medicine products: market entry as MEDICINE. *Advances in Integrative Medicine*. 2019; 6(S1): S63.
10. Yao D, Harnett J, **Hu H**, Ung COL. Key stakeholders’ perspectives on pharmacy practice about traditional Chinese medicines in China. *Advances in Integrative Medicine*. 2019; 6(S1): S113.
11. Zheng T, Harnett J, **Hu H**, Ung COL. The perception and use of herbal preparations by breastfeeding mothers in Macau – results of a cross-sectional survey. *Advances in Integrative Medicine*. 2019; 6(S1): S46.
12. Chen SQ, Meng H, Lai Y, Ung COL, **Hu H**. PRS59 Social understanding of lung function examination in China: a cross-sectional survey. *Value in Health*. 2018; *21:* S414.
13. Lai Y, Bie R, Suo S, Shi H, Chen S, Ung COL, **Hu H**. PHP51 Utilization of monoclonal antibody in China: a study from national market access view. *Value in Health*. 2018; 21: S159.
14. Salem A, Ramos M, **Hu H**, Zhong H, Lamotte M. PRS31 The economic impact of optimized post-hospitalization management for an exacerbation in COPD patients in China. *Value in Health*. 2018; 21: S409.
15. Suo S, Ung COL, Shi H, Chen S, **Hu H**. PHP208 Physicians’ improvement suggestions for enteral nutrition care in China: a cross-sectional survey. *Value in Health.* 2018; 21: S185.
16. Chung CC, **Hu H**\*. Entrepreneurship, knowledge spilled-over and the evolution of the innovation system: The case of pharmaceutical innovation system in China. Book of Abstracts Eu-SPRI Annual Conference Vienna 2017. Vienna, Austrina: 363-365.
17. Hu H\*, Hafsi T. 2014. *Reshaping logic through business model innovation: When traditional Chinese medicine meets western medicine in the antidepressant industry of China.* SMS Special Conference, Sydney, December, 2014.
18. Hu, H., & Hafsi, T. 2012. *Change through mirroring: Standardization of Chinese herb slice between Traditional Chinese Medicine and Western Medicine*. The 28th EGOS Colloquium; Helsinki, Finland. July 2012.
19. Zhang, L., & Hu, H. 2011. *Using complex products and systems in the pharmaceutical innovation: Case study of R&D project in pharmaceutical industry*. International Conference on Asia Pacific Business Innovation and Technology Management, Dalian, China.
20. Lai, Y. F., & Hu, H. 2011. *Crafting network competence for pharmaceutical innovation of Chinese pharmaceutical companies*. International Conference on Asia Pacific Business Innovation and Technology Management, Dalian, China.
21. Kuan, W. C., & Hu, H. 2011. *Institutional actors in different stages of industrial cluster: The case of Montreal and Zhangjiang*. International Conference on Asia Pacific Business Innovation and Technology Management, Bali, Indonesia.
22. Gao, Hua., Hu, Hao., & Kuan, W. C. 2010. *Co-evolution of management and technological innovation: A case study of WANDONG Medical Equipment Company in China*. The 10th International Conference on Industrial Management, Beijing.
23. Bao, F. F. & Hu, H. 2010. *From sales agent to international competitor: Catch-up strategy of Mindray in the global market*. The 10th International Conference on Industrial Management, Beijing.
24. Fan, M. X., Hu, H., Zhao, H. Y., & Wang, Y. T. 2009. *Research on the current status of Contract Research Organization in China*. The 7th International Pharmaceutical High Technology Conference, Chongqing.
25. Yu, W. X., Hu, H., Shi, L. W., & Wang, Y. T. 2009, September. *The innovation mechanism of project management in Chinese pharmaceutical enterprises*. The 7th International Pharmaceutical High Technology Conference, Chongqing.
26. Hu, H., & Hafsi, T. 2008. *Strategic capabilities and strategic choice in situations of transition: A study of firms’ behaviour in East and West China*. The Annual Conference of Administrative Sciences Association of Canada, Halifax.

**10. Patent**

1. Method and device for transforming two-dimensional code (一種二維碼轉化的方法及裝置). China Patent: ZL201610670997.0
2. 黃芪種子蛋白及其在抗運動疲勞功能食品中的應用. China Patent: ZL 2017 10580674.7

**11. Course teaching since 09/2014:**

* Ph.D. courses
  + “Advanced Topics in Medicinal Administration (CMED8011)” (2017-present)
  + “Research Ethics (GRSC801)” (2014-2015)
* Master courses
  + “International Business and Law for Medicine (CMED7005) (2014-present)”
  + “Research Methodology (CMED7021) (2016-present)”
* Undergraduate course
  + “Health Industry Management” (BIOB254) (2014)

**12. Faculty and University-level service**

* Member of the **Academic Staff Assessment Development Committee** at ICMS (2021-)
* Member of the **Staff and Student Consultative Committee** (2015-2023)
* Member of the **Committee for Student Disability Policy & Service** (2015-present)
* College affiliate ofthe **Henry Fok Pearl Jubilee College** (2015-present)
* Master program coordinator of **Medicinal Administration Program** (MAD) (2014-2015)
* Coordinator for the **Forum on Development Status and Trend of Macao Pharmaceutical Systems** (2017, 2018, 2019)
* Member of the University and Faulty-level academic staff promotion advisory committees
* Pedagogic Committee in ICMS
* Ad hoc panel member for patent application meeting in the University of Macau

**13. External (government, community & academic) service**

* Associate editor of ***npj* Digital Medicine** (01/08/2024-)
* Associate editor of **Frontiers in Medical Technology** (01/01/2019-)
* Associate editor of **Cost Effectiveness and Resource Allocation** (16/08/2023-)
* Editorial board member of **BMC Complementary Medicine and Therapies** (2017-present)
* Editorial board member of **BMC Public Health** (31/05/2023-)
* Editorial board member of **Pharmacoepidemiology** (30/08/2023-)
* Academic editor of **PLOS Complex Systems** (2023-)
* Scientific member of **Management International journal** (2014-2017)
* Guest editor for **Frontiers in Pharmacology** (2019)
* Guest editor for **Frontiers in Digital Health** (2024)
* Guest editor for **Pharmacoepidemiology** journal “Bridging Pharmacoepidemiology and Pharmacoeconomics for Better Healthcare Outcomes” (2023)
* Co-founder and president of the **Macao Society for Medicinal Administration** (2019-present)
* Secretary-general of the **Macao Pharmacology Association** (2019-present)
* Academic secretary for the **International Society for Chinese Medicines** (2008-2019)
* Standing committee member of the **Specialty Committee of Drug Utilization Evaluation and Clinical Research at the Guangdong Pharmaceutical Association** (2018-present)
* Standing committee member of the **Specialty Committee of Pharmacoeconomics at the Chinese Research Hospital Association** (2018-present)
* Standing committee member of the **Specialty Committee of Drug Distribution at the China Society for Drug Regulation** (2020-).
* Member of the **Hong Kong Chapter of the International Society for Pharmacoeconomics and Outcomes Research** (2017-present)
* Vice chairman of the **Health Industry Alliance of Food Nutrition Guangdong of Hong Kong and Macau Bay Area** (2019-present)
* Scientific advisor for the **Innovation Project Medical Review Committee (IPMRC) of AstraZeneca** (2019-present)
* Scientific advisor for the **Guangdong-Macao TCM Science and Technology Park** (2016-2017)
* Add-hoc reviewers of several international referred journals (2008-present)

**14. Professional Qualifications**

* Visiting Professor, (2017-present): School of Economics and Management (Beijing Jiaotong University)
* Guest Researcher (2017-present): National Center for Licensed Pharmacist (China Pharmaceutical University)
* Guest Researcher (2015-present): State Key lab for Hydraulics and Mountain River Engineering (Sichuan University)
* Guest Researcher (2013-present): International Research Center for Medicinal Administration (Peking University)
* Research Fellow (2006-2012): CRIMT (University of Montreal)